Content Library

Past Presentations from the Neoantigen Event Series

 GenScript Interview

Raymond Miller, Ph.D. Senior Global Product Manager, Therapeutic Materials GenScript Biotech Corporation

Using Predictive Bioinformatics Algorithms to Determine Neoantigen Peptide Synthesis Difficulty & Subsequent Production Methodology

Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences

Beyond Algorithms: The ATLAS Bioassay Method for Neoantigen Identification and Characterization


Andrew Allen, CEO, Gritstone Oncology

Using Normal Immune Responses as Engine for Cancer Immunotherapy


Gavin MacBeath, Chief Scientific Officer, TScan Therapeutics

A Genome-Wide Approach to Discovering Novel Targets & TCRs for T-Cell Therapy


Hans-Peter Gerber, CSO & SVP, 3T Biosciences

Identification of Novel Shared Targets in Solid Tumors